PRESS RELEASES

FDA Advisory Committee Provides Clear Path Forward For Development of Amyloid Imaging Agents For Alzheimer’s Disease

Avid Radiopharmaceuticals Presents Clinical Results of Novel Amyloid Imaging Agents at the 2008 International Conference on Alzheimer’s Disease (ICAD)

Avid Appoints Richard A. Baron as Chief Financial Officer

Phase I Data from Avid Radiopharmaceuticals’ Alzheimer’s and Parkinson’s Disease Imaging Programs to be Presented at the 55th Annual Society of Nuclear Medicine Meeting

Avid Radiopharmaceuticals Initiates First Phase II Trial of Novel Compound for Imaging Alzheimer’s Disease

Imaging Agent from Avid Radiopharmaceuticals to be Licensed by Bayer Schering Pharma for Early Detection of Alzheimer's Disease

Molecular Imaging of Diabetes Selected as 2007 Small Animal Image of the Year

Avid Radiopharmaceuticals Appoints Ernest Mario, Ph.D. to Board of Directors

Avid RP Closes $26 Million Series C Financing

MDS Nordion Enters Collaboration Agreement with Avid Radiopharmaceuticals on Imaging Compounds for Alzheimer's Disease

Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimer's Disease Presented at AD/PD Meeting

Schering AG and Avid Radiopharmaceuticals to develop novel approach for early diagnostic imaging of Alzheimer's Disease

Avid RP strengthens its drug and business development capabilities with the addition of three industry veterans

Avid RP Closes $8.9 Million Financing to Support Development of Alzheimer's Diagnostic and Prognostic Agents

Avid selected as Enterprise Award Finalist: Life Sciences Start-Up Company of the Year